Cantor Fitzgerald Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Roth Capital Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Sell, $1 PT
July 24, 2015 7:32 AM EDTRoth Capital downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Buy to Sell with a price target of $1.00 (from $5.50).
Analyst Joseph Pantginis commented, "Sunesis provided the much anticipated regulatory updates from both the FDA and EMA with mixed results, though we believe the... More
Cowen Downgrades Sunesis Pharmaceuticals Inc. (SNSS) to Market Perform
July 24, 2015 6:30 AM EDTCowen downgraded Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS) from Outperform to Market Perform.
Analyst Eric Schmidt commented, "Sunesis announced that recent FDA discussions were not supportive of an NDA filing for vosaroxin. The company will proceed with an MAA filing in... More
Sunesis Pharmaceuticals (SNSS) Issues Update on Meetings with EMA, FDA Over Vosaroxin in AML
July 23, 2015 4:22 PM EDTSunesis Pharmaceuticals (NASDAQ: SNSS) announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) regarding a potential path toward marketing authorization for vosaroxin as a treatment for acute myeloid leukemia (AML) in Europe and the United States.
With respect to Europe, the company recently met separately with the Rapporteur (United Kingdom) and Co-Rapporteur (Netherlands) assigned to provide advice and guide the company through the Marketing Authorization Application (MAA) process. Based on these substantive discussions, the company was encouraged to proceed with an MAA... More
